UBS Upgrades Rivian to Neutral With a $16 PT

Feb 13, 2026· 1 min read· Reproduced verbatim
Rating
Hold
Price target
$16
Previous
$15
Implied upside
+14%

UBS analyst Joseph Spak upgraded on February 13, 2026, Rivian from ‘Sell’ to ‘Neutral’ with a price target of $16 (from $15).

“We believe the near-term risk/reward is more balanced at current levels as our prior rating was in part valuation based.

Ultimately, the RIVN investment case is about the company progressing to a being a larger, and ultimately profitable, company.

We have been, and continue to be, excited about the product, the product pipeline and the brand.

We just had concerns that valuation had gotten ahead of itself. 2026 guidance itself encapsulates some of the upside potential with downside risk.

RIVN guided 2026 deliveries to 62-67k, which is better than we feared, and if they are able to execute to that, it portends a solid exit rate by which one can imagine an even stronger 2027 and beyond.

However, the flip side is we struggle to see upside to 2026 guidance, and downside seems possible as:

  1. guidance implies ~45k units in 2H, a strong ramp;
  2. it implies ~22k R2 deliveries, and while we don’t doubt initial demand, that may require near flawless production execution.

Thus, we see limited positive revisions in the near term.

Further, company is still burning cash and we don’t see positive EBITDA for a number of years.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.